Want to see FR:AELIS full AI Analyst Report?
Top Page
Aelis Farma SA
(AELIS)
Select Model
Select Model
Rating:43Neutral
Price Target:
€0.93
▼(-19.39% Downside)
Action:Reiterated
Date:04/27/26
The score is primarily held down by weak financial performance—persistent losses, deteriorated profitability, and ongoing cash burn that increases financing risk. Technicals are also slightly negative with the stock below key moving averages and soft momentum. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Targeted CNS R&D Focus
Aelis’s narrow scientific focus on small-molecule modulation of CNS and peripheral signaling provides a durable strategic advantage: concentrated domain expertise, clearer development pathways, and higher appeal to partners or acquirers versus unfocused biotech peers, sustaining long-term optionality.
Negative Factors
Persistent cash burn
Operating and free cash flows have been negative across 2022–2025, indicating sustained cash burn and dependence on external funding. This persistent outflow pattern raises dilution and recapitalization risk and constrains strategic flexibility for multi-year R&D programs absent fresh financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Targeted CNS R&D Focus
Aelis’s narrow scientific focus on small-molecule modulation of CNS and peripheral signaling provides a durable strategic advantage: concentrated domain expertise, clearer development pathways, and higher appeal to partners or acquirers versus unfocused biotech peers, sustaining long-term optionality.
Read all positive factors
Aelis Farma SA (AELIS) vs. iShares MSCI France ETF (EWQ)
Market Cap
€13.17M
Dividend YieldN/A
Average Volume (3M)48.51K
Price to Earnings (P/E)―
Beta (1Y)0.67
Revenue Growth-100.00%
EPS Growth15.20%
CountryFR
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.47
Shares Outstanding13,706,586
10 Day Avg. Volume44,132
30 Day Avg. Volume48,508
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)3.49
Price to Sales (P/S)7.43
P/FCF Ratio-2.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.17
Revenue Forecast (FY)€12.40M
Aelis Farma SA Business Overview & Revenue Model
Company Description
Aelis Farma S.A., a French biotechnology company founded in 2013 and headquartered in Bordeaux, is dedicated to the discovery and development of treatments for brain-related illnesses. The firm's research pipeline primarily focuses on signaling-sp...
How the Company Makes Money
null...
Aelis Farma SA Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
41
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.08M | 2.68M | 9.05M | 3.81M | 9.07M |
| Gross Profit | -279.00K | 2.68M | 9.05M | 3.81M | 9.07M |
| EBITDA | -8.00M | -7.18M | -6.35M | -16.23M | 844.00K |
| Net Income | -6.43M | -7.46M | -5.08M | -14.29M | 574.00K |
Balance Sheet | |||||
| Total Assets | 12.05M | 19.71M | 26.28M | 39.22M | 28.31M |
| Cash, Cash Equivalents and Short-Term Investments | 8.21M | 14.05M | 20.23M | 34.40M | 24.71M |
| Total Debt | 6.60M | 6.25M | 4.04M | 3.82M | 6.41M |
| Total Liabilities | 7.61M | 9.59M | 13.08M | 19.43M | 27.41M |
| Stockholders Equity | 4.44M | 10.12M | 13.20M | 19.79M | 899.00K |
Cash Flow | |||||
| Free Cash Flow | -5.39M | -11.72M | -12.67M | -13.19M | 18.76M |
| Operating Cash Flow | -5.38M | -11.53M | -12.59M | -13.05M | 18.97M |
| Investing Cash Flow | -841.00K | -190.00K | -88.00K | -86.00K | -212.00K |
| Financing Cash Flow | 538.00K | 5.81M | -1.34M | 22.10M | 180.00K |
Aelis Farma SA Technical Analysis
Negative
1.15
Price Trends
1.19
Negative
1.26
Negative
1.22
Negative
Market Momentum
-0.07
Positive
30.25
Neutral
6.58
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:AELIS, the sentiment is Negative. The current price of 1.15 is above the 20-day moving average (MA) of 1.09, below the 50-day MA of 1.19, and below the 200-day MA of 1.22, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 30.25 is Neutral, neither overbought nor oversold. The STOCH value of 6.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:AELIS.
Aelis Farma SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | €11.04M | -0.79 | ― | ― | 249.95% | 33.78% | |
45 Neutral | €18.84M | -0.99 | 51.23% | ― | -99.93% | 44.53% | |
43 Neutral | €13.17M | -2.04 | ― | ― | -100.00% | 15.20% | |
42 Neutral | €15.58M | -1.49 | ― | ― | 20.77% | -36.61% | |
42 Neutral | €1.83M | -0.02 | 92.02% | ― | ― | 84.60% |
* Healthcare Sector Average
FR:AELIS
Aelis Farma SA
0.96
-0.02
-1.94%
FR:POXEL
Poxel SA
0.21
-0.29
-58.16%
FR:SIGHT
GenSight Biologics SA
0.08
-0.12
-60.20%
FR:ALDVI
Advicenne SA
1.07
-0.31
-22.74%
FR:ALBPS
Biophytis SA
0.02
-0.12
-88.55%
FR:ALNFL
NFL Biosciences SA
0.84
-0.26
-23.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.